Shire to separate ADHD drugs ahead of possible spin-off, cuts outlook
LONDON (Reuters) - London-listed pharmaceutical group Shire said on Monday it would create two distinct business units for its rare disease and hyperactivity medicines ahead of deciding later this year whether to spin off the latter into a separately listed group.
from Reuters: Health News http://reut.rs/2ElrqJa
http://bit.ly/2zwRqiM